Nivolumab Induced Hepatocanalicular Cholestasis and Liver Rejection in a Patient With Lung Cancer and Liver Transplant

J Thorac Oncol. 2020 Sep;15(9):e149-e150. doi: 10.1016/j.jtho.2020.01.026.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Cholestasis*
  • Humans
  • Liver
  • Liver Transplantation*
  • Lung Neoplasms* / drug therapy
  • Nivolumab / adverse effects

Substances

  • Nivolumab